Articles On Rhythm Biosciences (ASX:RHY)

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Resources and tech stocks led the ASX back into positive territory Thursday. After a drop yesterday, led by tech, the bourse rebounded with the ASX 200 closing 0.52% higher. Resources led gaining 1.51% and tech gaining 2.6%. The only sector...

The ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of the bourse down with it. The ASX 200 retreated 0.7% to close at 7,379 points while the ASX Emerging Companies Index lost 1.06%, closing at 2...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.25% to 7,334.5 points. Four ASX shares that are not letting that hold them back are list...

The Rhythm Biosciences Ltd (ASX: RHY) share price has been a strong performer on Thursday. In afternoon trade, the early cancer detection-focused predictive diagnostics company’s shares are up 6% to 90 cents. This latest gain means the Rhy...

Wall Street mixed as US Federal Reserve says inflation is transitionary US stock markets finished in mixed territories, as investors digested US Fed chairman Jerome Powell’s testimony before a House panel. The Dow Jones finished 0.13% highe...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Summary The ASX 200 traded lower by 35.20 points or 0.48% at 7,351, weighed down by sharp selling in materials and energy stocks. The market sentiment was dampened by report that the US Fed may announce sooner-than-expected rise in int...

The ASX climbed briefly past 7,400 points in intra-day trade but ultimately closed just short of the milestone at 7,.368, which was 0.09 per cent higher than yesterday. However, the ASX Emerging Companies Index fell by over 1 per cent for t...

Summary The ASX 200 sets a new record by crossing 7,400 level for the first time. The benchmark trades higher by 23.50 points or 0.32% at 7,403 by afternoon. Nine of the 11 sectors are trading higher, with energy gaining the most, ris...

The Rhythm Biosciences Ltd (ASX: RHY) share price is rising following the company’s latest addition to its ColoSTAT clinical trial. In early morning trade, the medical device company’s shares were up 3.57% to $1.015 before retreating to $1...

Wall Street nervous as Fed goes into a two-day policy meeting All major indices in the US fell on Tuesday, ahead of a key policy announcement from the US central bank this Thursday (US time). The Dow Jones fell by 0.27%, S&P 500 by 0.20...

Point of care diagnostic test provider Lumos Diagnostics (ASX:LDX) is set to list on the ASX on July 5. The company was founded in Melbourne in 2015 and is still headquartered there but has manufacturing facilities in California and Florida...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

The positive start to the week has continued for ASX stocks. The ASX 200 closed at 7,066, 0.60 per cent higher than yesterday although it is still 100 points off its record high reached in February 2020 and last week. Meanwhile, the ASX Eme...

A series of ASX announcements has attracted investors to the biotech sector today, lifting the share prices of some of its players. The buying frenzy has also lifted the broader health sector by as high as 1 per cent earlier today, but is c...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company’s strategic update to FY22. During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%. Rhythm moves ahead with strategic plans Inv...

The ASX finished the day in the red and the tech sector dropped more than any other sector. The ASX 200 closed at 7,062 which was 0.48 per cent down from yesterday and tech stocks shed over 3.5 per cent. The only other sector to fall over 1...

The Rhythm Biosciences Ltd (ASX: RHY) share price is a strong mover today following the release of its ColoSTAT results. Rhythm’s ColoSTAT is an experimental test-kit that is being trialled as a low-cost, easy-to-use blood test to detect c...

Summary Diagnostics company Rhythm Biosciences has confirmed that LRF enhancements have shown to improve ColoSTAT® results. Cannabis medicines developer Zelira Therapeutics has entered into a partnership with Alternative Solutions for...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

The Rhythm Biosciences Ltd (ASX: RHY) share price slid at market open today despite announcing a positive update in regards to its accreditation. In early morning trade, the medical device company’s shares are swapping hands for $1.09, dow...

On this day last year, global stocks capped off a historic one-month collapse with another epic fall. While no one knew at the time, that marked the COVID-19 nadir. Over the course of the following week, governments around the world said ju...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

The Rhythm Biosciences Ltd (ASX: RHY) share price has opened higher on Tuesday after the successful completion of Study 6 for its ColoSTAT product. At the time of writing, the Rhythm share price is trading at $1.60, up 6.33%. Let’s take a...

The best ASX stocks since COVID-19 have completely outperformed their peers with the top 10 up over 2000 per cent. A year since COVID-19 began life has changed for most ASX companies, but the best 10 have done particularly well. Stockhead h...

Strong performing ASX healthcare shares came few and far between in February. The S&P/ASX Health Care Index (ASX: XHJ) was down 3% for the month, compared to the 1% increase in the ASX 200.   From respiratory devices, vaccine producers...

The Rhythm Biosciences Ltd (ASX: RHY) share price is sinking today, despite announcing an additional site to its ColoSTAT clinical trial program. During the first hour of open, shares in the medical device company fell to an intraday low o...

Rhythm Biosciences (ASX:RHY) is showing it has its crap together – literally – as it works to make faecal occult ... Read More The post Rhythm keeps flying after validating prototype commercial test-kits appeared first on Stockhead.

Summary ASX-listed cancer diagnostics player Rhythm Biosciences revealed that the initial manufacturing of ColoSTAT® test kits had been completed. The diagnostics player is conducting performance and verification testing of test-kits....

It seems like Rhythm Biosciences Ltd (ASX: RHY) can do no wrong by investors at the moment. Today, the company’s shares have risen to another all-time high record following the update on the initial manufacturing of ColoSTAT. During early...

Small caps bounced back solidly from yesterday’s losses with the Small Ordinaries index finished Tuesday up 1.58 per cent to 3,123.7. The ASX 200 rose by 1.19 per cent to 6,742.6 however the Emerging Companies nano-cap index only rose by 0....

Shares in Rhythm Biosciences Ltd (ASX: RHY) are soaring higher during early afternoon trade. This comes after the company announced it has added two extra clinical trial sites for its ColoSTAT study. Rhythm’s ColoSTAT is an experimental te...

The Rhythm Biosciences Ltd (ASX: RHY) share price roared over 12% higher yesterday to close at $1.18. Over the past six-month period, the Rhythm Biosciences share price has thundered over a staggering 1,300%. Rhythm Biosciences share price...

If you to know where fund managers and investors (the famous and the unknown alike) are putting their money, we’ve ... Read More The post Trading Places: Guess how much this shareholder made out of Rhythm Biosciences in just 4 months appear...

Rhythm Biosciences leads an otherwise mildly positive two weeks for the small-cap health care sector, with 64 companies gaining ground ... Read More The post Check Up: Rhythm Biosciences shares just keep on soaring appeared first on Stockhe...

At time of writing the share price of Rhythm Biosciences Ltd [ASX:RHY] is trading at $1.37, up 5.79%. Rhythm Biosciences experienced explosive growth in its share price throughout 2020, moving up over 3,720%. The post Rhythm Biosciences Sha...

At time of writing the share price of Rhythm Biosciences Ltd [ASX:RHY] is trading at $1.37, up 5.79%. Rhythm Biosciences experienced explosive growth in its share price throughout 2020, moving up over 3,720%. The post Rhythm Biosciences Sha...

The Rhythm Biosciences Ltd (ASX: RHY) share price has continued its positive run on Tuesday. At one stage, the medical device company’s shares were up 15% to a record high of $1.30. This is almost 1,000% higher than this time last year, ma...

While most ASX companies already have products sold in the market and have built sales traction, there are also companies that are still preparing for market launch. Here I’ve listed down three ASX small cap companies that are preparing to...

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

The Rhythm Biosciences Ltd (ASX: RHY) share price is climbing today after the company was granted a United States patent for ColoSTAT. At the time of writing, the Rhythm share price is up 5% to 84 cents. Rhythm develops and commercialises...